Capricor Therapeutics, Inc.

As of July 17, 2025, Capricor Therapeutics, Inc. shows a bearish trend with weak strength indicators, despite a 25% one-year return, as year-to-date performance is down 53.62%, significantly underperforming the S&P 500.

As of November 10, 2022, Capricor Therapeutics, Inc. is considered risky and overvalued, with a high Price to Book Value of 5.10, negative EV to EBIT and EBITDA ratios, a troubling -43.14% Return on Equity, and a year-to-date return of -53.62%, significantly underperforming the S&P 500.

As of November 10, 2022, Capricor Therapeutics, Inc. is considered risky and overvalued due to its negative P/E ratio, high price-to-book value, and poor stock performance, especially compared to peers like Chimerix and CytomX.

As of June 20, 2025, Capricor Therapeutics, Inc. shows a bearish trend with dominant negative indicators, despite some mixed signals in the monthly timeframe.

As of March 2022, the management team of Capricor Therapeutics, Inc. includes Dr. Frank Litvack (Independent Executive Chairman), Dr. Linda Marban (President and CEO), and several independent directors: Mr. Joshua Kazam, Mr. Earl Collier, Mr. George Dunbar, Mr. Louis Grasmick, and Mr. Louis Manzo. They oversee the company's strategic direction and operations.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing regenerative medicine therapies for cardiovascular diseases. As of March 2025, it has a market cap of $557.18 million and reported a net profit loss of $24 million.

As of Jun 18, Capricor Therapeutics, Inc. has a market capitalization of 557.18 million, with net sales of 17.36 million and a net profit of -55.07 million over the latest four quarters. The company reported shareholder's funds of 145.46 million and total assets of 170.48 million as of Dec 24.